The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research NetworkMature B cell neoplasms: retrospective analysis of 93 cases diagnosed between 2011 and 2014 in a University Hospital in southern BrazilA genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN).Non-Hodgkin lymphoma and autoimmunity: does gender matter?Destined to die in hospital? Systematic review and meta-analysis of place of death in haematological malignancyEmergency admission and survival from aggressive non-Hodgkin lymphoma: A report from the UK's population-based Haematological Malignancy Research NetworkHaematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data.Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional studyPreferred and actual place of death in haematological malignancy.Place of death in haematological malignancy: variations by disease sub-type and time from diagnosis to deathTime-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research NetworkDoes gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy.Occupational exposure to endocrine disruptors and lymphoma risk in a multi-centric European study.Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network.Distribution and features of hematological malignancies in Eastern Morocco: a retrospective multicenter study over 5 yearsThe impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study.Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma.Self-reported history of infections and the risk of non-Hodgkin lymphoma: an InterLymph pooled analysis.Menstrual and reproductive factors, and hormonal contraception use: associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case-control studies.Geographic distribution of hematopoietic cancers in the Nile delta of Egypt.Rational design of Raman-labeled nanoparticles for a dual-modality, light scattering immunoassay on a polystyrene substrate.Variations in specialist palliative care referrals: findings from a population-based patient cohort of acute myeloid leukaemia, diffuse large B-cell lymphoma and myelomaEpiglottic diffuse B-cell malignant lymphoma: A case report.Postmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case-control studiesA Pooled Analysis of Reproductive Factors, Exogenous Hormone Use, and Risk of Multiple Myeloma among Women in the International Multiple Myeloma ConsortiumBody size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study.MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphomaInhibition of estrogen biosynthesis enhances lymphoma growth in mice.Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort.Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort.Haematological malignancies: the rationale for integrated haematopathology services, key elements of organization and wider contribution to patient care.Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.Determinants of hospital death in haematological cancers: findings from a qualitative study.Epidemiology of chronic myeloid leukaemia: an update.The clinical impact of staging bone marrow examination on treatment decisions and prognostic assessment of lymphoma patients.Clinical study of l-asparaginase in the treatment of extranodal NK/T-cell lymphoma, nasal type.Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
P2860
Q24597424-5AFF614C-4E0A-4C50-8F34-C0FD58DAECCAQ28252000-5364BE2B-03CA-4B22-90C3-DAC983CB06C0Q28395001-AF0D9189-DBEA-4692-9BDE-F353D560D66EQ28943455-108DFF5F-8DAD-4CDD-80B1-4CD5D5889EAAQ30244110-302C5AB4-AEBA-4F7B-ADB7-EB969FB1DB36Q31111112-474C26FF-71D6-466F-B582-B3C5639DD141Q33391942-A5D640B3-3C68-486A-AF34-23094A99D74DQ33591670-C9215422-69ED-4555-8497-4C723900E955Q33732402-46809C06-2BBA-485A-AC06-429C2720900EQ33791668-CFCD7D95-E358-4831-8B53-14B82F19B4C2Q33860644-DFC25338-6B8B-4D7A-9447-709E1DF06054Q33886101-8943F82D-6275-4829-9BAE-39EC09BDF4F9Q34243733-A46BF8D3-CC9F-4F9A-8586-5D4FCB37FB38Q34252897-E25803C0-4AEB-4CE6-A2A4-626DA34D0390Q34463466-D1368F5A-30A3-495B-B7BB-E36212639A62Q35275008-493542CC-2BA6-49C5-BB84-DDD50B78497FQ35677959-5524E7E0-5470-4454-8507-940D6D681DFDQ35936061-34A6CC1F-7225-4EC9-B5CE-96E0D4443AE7Q36069700-2564FEC6-D20C-400A-B52E-757C85328802Q36093288-DC3DC12A-9C87-4661-975A-560F08025E97Q36120539-94298192-7BA9-4CA2-B3E9-84DA4FCA440FQ36182352-EDBB3ED1-0AE1-4608-8B0D-DE01791B3A2AQ36278117-C336E37A-1D9E-4333-A538-0186A9817159Q36443172-D39FDB67-30CA-495A-85CB-C583E117219AQ36475705-9F6DFFDB-E6C4-4ED2-86BD-96287CA86FB3Q36502300-2AA7A9A0-7CA0-4370-B92A-F9B80D986540Q36551642-87C356B0-32CE-4191-A0B9-003E3050B2D7Q36556093-310218E9-0281-4525-9C79-D526078E8376Q36924751-895F226E-9E4C-4B3B-8E13-BA60722F046AQ37142412-EAD9C504-9AA4-4B3B-88D3-47EEEE477E28Q37190419-777A6616-2E1B-41A6-922B-CA5494F71279Q37517333-8DE34AB1-8582-4939-AE5C-4C826143C50BQ37647935-BFAE9F0B-26C2-4A7C-8BF3-DECA70C2889AQ37831962-2341B966-EFAB-4AAA-9E45-E62BC65DBAD0Q37884384-DE8E6825-45A4-4A93-9E64-CF5EADDBFA0AQ38370017-357F3768-3FE3-407C-B206-AC8FA8A01B2FQ38392709-72BECBB6-CD31-4E14-BC82-59BAE6837CD1Q38415030-95CBF209-A69D-4E28-90F5-C5B173C14A33Q38433407-6A9FB302-C175-467B-A70C-19DD2D70EAADQ40140077-5994FA1C-355C-431B-BF09-EC4FBBA5E5D1
P2860
The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The Haematological Malignancy ...... gy and health service research
@ast
The Haematological Malignancy ...... gy and health service research
@en
The Haematological Malignancy ...... gy and health service research
@en-gb
The Haematological Malignancy ...... gy and health service research
@nl
type
label
The Haematological Malignancy ...... gy and health service research
@ast
The Haematological Malignancy ...... gy and health service research
@en
The Haematological Malignancy ...... gy and health service research
@en-gb
The Haematological Malignancy ...... gy and health service research
@nl
prefLabel
The Haematological Malignancy ...... gy and health service research
@ast
The Haematological Malignancy ...... gy and health service research
@en
The Haematological Malignancy ...... gy and health service research
@en-gb
The Haematological Malignancy ...... gy and health service research
@nl
P2093
P2860
P3181
P1476
The Haematological Malignancy ...... gy and health service research
@en
P2093
Alexandra Smith
Andrew Jack
Richard Jones
Russell Patmore
P2860
P304
P3181
P356
10.1111/J.1365-2141.2009.08010.X
P407
P50
P577
2010-03-01T00:00:00Z